0.0722 USD
-0.05 (-42.97%)
0.093 USD
+0.02 (+28.81%)
NMTR gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. NMTR may be in some trouble as it scores bad on both profitability and health. NMTR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year NMTR has reported negative net income.
- In the past year NMTR has reported a negative cash flow from operations.
1.2 Ratios
- NMTR has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NMTR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, NMTR has more shares outstanding
- NMTR has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -50.22, we must say that NMTR is in the distress zone and has some risk of bankruptcy.
- NMTR's Altman-Z score of -50.22 is on the low side compared to the rest of the industry. NMTR is outperformed by 95.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -50.22 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.59 indicates that NMTR may have some problems paying its short term obligations.
- NMTR has a worse Current ratio (0.59) than 92.96% of its industry peers.
- A Quick Ratio of 0.59 indicates that NMTR may have some problems paying its short term obligations.
- NMTR's Quick ratio of 0.59 is on the low side compared to the rest of the industry. NMTR is outperformed by 91.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
- NMTR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.12%.
EPS 1Y (TTM)-8.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 33.03% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.27%
EPS Next 2Y27%
EPS Next 3Y18.37%
EPS Next 5Y33.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- NMTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year NMTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NMTR's earnings are expected to grow with 18.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27%
EPS Next 3Y18.37%
5. Dividend
5.1 Amount
- NMTR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.0722
-0.05 (-42.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2023-05-15/amc
Earnings (Next)08-14 2023-08-14/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners3.91%
Ins Owner Change0%
Market Cap1.04M
Revenue(TTM)N/A
Net Income(TTM)-46.28M
Analysts80
Price Target10.58 (14553.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.44%
Min EPS beat(2)-28.53%
Max EPS beat(2)-18.34%
EPS beat(4)2
Avg EPS beat(4)-6.77%
Min EPS beat(4)-28.53%
Max EPS beat(4)13.92%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-49.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.93%
EPS NY rev (1m)44.63%
EPS NY rev (3m)44.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.46
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -50.22 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)66.06%
Cap/Depr(5y)59.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.5%
EPS Next Y58.27%
EPS Next 2Y27%
EPS Next 3Y18.37%
EPS Next 5Y33.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.86%
OCF growth 3YN/A
OCF growth 5YN/A
9 METERS BIOPHARMA INC / NMTR FAQ
What is the ChartMill fundamental rating of 9 METERS BIOPHARMA INC (NMTR) stock?
ChartMill assigns a fundamental rating of 0 / 10 to NMTR.
What is the valuation status of 9 METERS BIOPHARMA INC (NMTR) stock?
ChartMill assigns a valuation rating of 0 / 10 to 9 METERS BIOPHARMA INC (NMTR). This can be considered as Overvalued.
Can you provide the profitability details for 9 METERS BIOPHARMA INC?
9 METERS BIOPHARMA INC (NMTR) has a profitability rating of 0 / 10.
What is the financial health of 9 METERS BIOPHARMA INC (NMTR) stock?
The financial health rating of 9 METERS BIOPHARMA INC (NMTR) is 0 / 10.